MicroRNA expression profile analysis reveals diagnostic biomarker for human prostate cancer

Asian Pacific Journal of Cancer Prevention

Volumn 13, Issue 7, 2012, Pages 3313-3317

  Liu, Dong Fu ^a   Wu, Ji Tao ^a   Wang, Jian Ming ^a   Liu, Qing Zuo ^a   Gao, Zhen Li ^a   Liu, Yun Xiang ^a  

^a YANTAI YUHUANGDING HOSPITAL   (China)

Author keywords

MicroRNA; Network analysis; Pathway enrichment; Prostate cancer

Indexed keywords

EID: 84873586953     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2012.13.7.3313     Document Type: Article

References (48)

1. Ambs S, Prueitt RL, Yi M, et al (2008). Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res, 68, 6162-70.
2. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
3. Benjamini YH, Y (1995). Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the royal statistical society Series B (Methodological), 57, 289-300.
4. Berezikov E, Guryev V, van de Belt J, et al (2005). Phylogenetic shadowing and computational identification of human microRNA genes. Cell, 120, 21-4.
5. Bubendorf L, Schopfer A, Wagner U, et al (2000). Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients. Hum Pathol, 31, 578-83.
6. Chan JM, Jou RM, Carroll PR (2004). The relative impact and future burden of prostate cancer in the United States. J Urol, 172, S13-6; discussion S7.
7. Cummins JM, He Y, Leary RJ, et al (2006). The colorectal microRNAome. Proc Natl Acad Sci U S A, 103, 3687-92.
8. Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76.
9. Garcia DM, Baek D, Shin C, et al (2011). Weak seed-pairing stability and high target-site abundance decrease the proficiency of lsy-6 and other microRNAs. Nat Struct Mol Biol, 18, 1139-46.
10. Gautier L, Cope L, Bolstad BM, Irizarry RA (2004). affy-- analysis of Affymetrix GeneChip data at the probe level. Bioinformatics, 20, 307-15.
11. Hao P, Chen X, Geng H, et al (2004). Expression and implication of hypoxia inducible factor-1alpha in prostate neoplasm. J Huazhong Univ Sci Technolog Med Sci, 24, 593-5.
12. Horvath S, Zhang B, Carlson M, et al (2006). Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA, 103, 17402-7.
13. Iorio MV, Ferracin M, Liu CG, et al (2005). MicroRNA gene expression deregulation in human breast cancer. Cancer Res, 65, 7065-70.
14. Irizarry RA, Hobbs B, Collin F, et al (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics, 4, 249-64.
15. John B, Enright AJ, Aravin A, et al (2004). Human MicroRNA targets. PLoS Biol, 2, e363.
16. Kanehisa M (2002). The KEGG database. Novartis Found Symp, 247, 91-101; discussion -3, 19-28, 244-52.
17. Kimbro KS, Simons JW (2006). Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer, 13, 739-49.
18. Kozomara A, Griffiths-Jones S (2011). miRBase: integrating microRNA annotation and deep-sequencing data. Nucleic Acids Res, 39, D152-7.
19. Krek A, Grun D, Poy MN, et al (2005). Combinatorial microRNA target predictions. Nat Genet, 37, 495-500.
20. Lee EJ, Gusev Y, Jiang J, et al (2007). Expression profiling identifies microRNA signature in pancreatic cancer. Int J Cancer, 120, 1046-54.
21. Lee RC, Feinbaum RL, Ambros V (1993). The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell, 75, 843-54.
22. Linton DK, Hamdy FC (2004). Early diagnosis and surgical management of prostate cancer. Ann Urol (Paris), 38, 137-47.
23. Logothetis CJ, Lin SH (2005). Osteoblasts in prostate cancer metastasis to bone. Nat Rev Cancer, 5, 21-8.
24. Lu J, Getz G, Miska EA, et al (2005). MicroRNA expression profiles classify human cancers. Nature, 435, 834-8.
25. Mattie MD, Benz CC, Bowers J, et al (2006). Optimized high-throughput microRNA expression profiling provides novel biomarker assessment of clinical prostate and breast cancer biopsies. Mol Cancer, 5, 24.
26. McCarron SL, Edwards S, Evans PR, et al (2002). Influence of cytokine gene polymorphisms on the development of prostate cancer. Cancer Res, 62, 3369-72.
27. Min H, Yoon S (2010). Got target? Computational methods for microRNA target prediction and their extension. Exp Mol Med, 42, 233-44.
28. Murakami Y, Yasuda T, Saigo K, et al (2006). Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene, 25, 2537- 45.
29. O'Donnell KA, Wentzel EA, Zeller KI, et al (2005). c-Myc-regulated microRNAs modulate E2F1 expression. Nature, 435, 839-43.
30. Ozen M, Creighton CJ, Ozdemir M, Ittmann M (2008). Widespread deregulation of microRNA expression in human prostate cancer. Oncogene, 27, 1788-93.
31. Porkka KP, Pfeiffer MJ, Waltering KK, et al (2007). MicroRNA expression profiling in prostate cancer. Cancer Res, 67, 6130-5.
32. Schaefer A, Jung M, Miller K, et al (2010). Suitable reference genes for relative quantification of miRNA expression in prostate cancer. Exp Mol Med, 42, 749-58.
33. Schaefer A, Jung M, Mollenkopf HJ, et al (2010). Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int J Cancer, 126, 1166-76.
34. Semenza GL (2003). Targeting HIF-1 for cancer therapy. Nat Rev Cancer, 3, 721-32.
35. Sempere LF, Christensen M, Silahtaroglu A, et al (2007). Altered MicroRNA expression confined to specific epithelial cell subpopulations in breast cancer. Cancer Res, 67, 11612-20.
36. Sfar S, Hassen E, Saad H, et al (2006). Association of VEGF genetic polymorphisms with prostate carcinoma risk and clinical outcome. Cytokine, 35, 21-8.
37. Shen MM, Abate-Shen C (2010). Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev, 24, 1967-2000.
38. Siegel R, Naishadham D, Jemal A (2012). Cancer statistics, 2012. CA Cancer J Clin, 62, 10-29.
39. Szklarczyk D, Franceschini A, Kuhn M, et al (2011). The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res, 39, D561-8.
40. Team RDC (2011). R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing.
41. Tong AW, Fulgham P, Jay C, et al (2009). MicroRNA profile analysis of human prostate cancers. Cancer Gene Ther, 16, 206-16.
42. van der Laan MJ, Dudoit S, Pollard KS (2004). Augmentation procedures for control of the generalized family-wise error rate and tail probabilities for the proportion of false positives. Stat Appl Genet Mol Biol, 3, Article15.
43. Volinia S, Calin GA, Liu CG, et al (2006). A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA, 103, 2257-61.
44. Wach S, Nolte E, Szczyrba J, et al (2012). MicroRNA profiles of prostate carcinoma detected by multiplatform microRNA screening. Int J Cancer, 130, 611-21.
45. Wang Y, Shao C, Shi CH, et al (2005). Change of the cell cycle after flutamide treatment in prostate cancer cells and its molecular mechanism. Asian J Androl, 7, 375-80.
46. Wightman B, Ha I, Ruvkun G (1993). Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell, 75, 855-62.
47. Zhang JF, Fu WM, He ML, et al (2011). MiRNA-20a promotes osteogenic differentiation of human mesenchymal stem cells by co-regulating BMP signaling. RNA Biol, 8.
48. Zhong H, Agani F, Baccala AA, et al (1998). Increased expression of hypoxia inducible factor-1alpha in rat and human prostate cancer. Cancer Res, 58, 5280-4.